特异性抑制经典补体途径可阻止大疱性类天疱疮真皮-表皮交界处C3沉积
大疱性类天疱疮以自身抗体和补体沿真皮-表皮交界处沉积为特征,标准治疗不良反应多。这项1期试验评估C1s抑制剂BIVV009在10例活动期或既往大疱性类天疱疮患者中的安全性和活性,每周60 mg/kg四次输注足以抑制所有患者的经典补体途径,5例基线有C3c沉积者中4例部分或完全消除,药物安全可耐受,支持进一步研究其疗效和安全性。
要点
- BIVV009每周60 mg/kg四次输注可抑制所有患者经典补体途径。
- 基线有C3c沉积的5例中4例部分或完全消除沉积。
- 老年患者中仅见轻中度不良事件,安全可耐受。
核心结论
- BIVV009在活动期或既往大疱性类天疱疮患者中安全可耐受,并能抑制经典补体途径、减少真皮-表皮交界处C3c沉积。
研究设计与样本
- 1期试验纳入10例活动期或既往大疱性类天疱疮患者,评估BIVV009的安全性和活性(NCT02502903)。
主要发现
- 每周60 mg/kg四次输注BIVV009足以抑制所有患者的经典补体途径,以CH50衡量。
- 基线有C3c沉积的5例患者中,4例沿真皮-表皮交界处的C3c沉积部分或完全消除。
- 仅报告轻中度不良事件如头痛、乏力;一例84岁有糖尿病和心力衰竭史的患者在治疗后观察期结束时发生致命性心脏失代偿,判定不太可能与研究药物相关。
关键数值与推荐
- BIVV009剂量为每周60 mg/kg,共四次输注。
- 经典补体途径抑制以CH50衡量。
- C3c沉积沿真皮-表皮交界处评估,5例基线有沉积者中4例部分或完全消除。
临床怎么用
- BIVV009作为补体靶向治疗在大疱性类天疱疮中显示初步安全性和活性,支持进一步开展疗效和安全性研究。
局限性
- 为1期试验,样本量10例,需进一步研究确认疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deposition of autoantibodies (α-BP180 and BP230) and complement along the dermal-epidermal-junction is a hallmark of bullous pemphigoid and was shown to be important for pathogenesis. Given the adverse effects of standard treatment (glucocorticoids, immunosuppressants), there is an unmet need for safe and effective therapies. In this phase 1 trial, we evaluated the safety and activity of BIVV009 (sutimlimab, previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903). Four weekly 60 mg/kg infusions of BIVV009 proved sufficient for inhibition of the classical complement pathway in all patients, as measured by CH50. C3c deposition along the dermal-epidermal junction was partially or completely abrogated in 4 of 5 patients, where it was present at baseline. BIVV009 was found to be safe and tolerable in this elderly population, with only mild to moderate adverse events reported (e.g., headache, fatigue). One serious adverse event (i.e., fatal cardiac decompensation) occurred at the end of the post-treatment observation period in an 84-year-old patient with a history of diabetes and heart failure, but was deemed unlikely to be related to the study drug. This trial provides the first results with a complement-targeting therapy in bullous pemphigoid, to our knowledge, and supports further studies on BIVV009's efficacy and safety in this population.
引用
- Freire PC, Muñoz CH, Derhaschnig U, et al. Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid. J Invest Dermatol. 2019. PMID: 31229501. doi:10.1016/j.jid.2019.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。